DEFR14A: Sharps Technology Seeks Massive Share Increase

Sharps Technology, Inc. files definitive proxy statement for its 2025 Annual Meeting, proposing a significant increase in authorized common stock and approval of a new equity incentive plan.

Summary

• Sharps Technology, Inc. will hold its 2025 Annual Meeting of Stockholders virtually on August 22, 2025, at 10:00 a.m. Eastern Time.
• Stockholders of record as of July 17, 2025, are entitled to vote.
• Key proposals include the election of six directors, ratification of PKF OConnor Davies LLP as the independent auditor for fiscal year ending December 31, 2025, and approval of the 2025 Equity Incentive Plan.
• A major proposal seeks to amend the articles of incorporation to increase authorized common stock from 1,666,667 shares to 500,000,000 shares.
• The company's Board of Directors unanimously recommends a vote FOR all proposals.
• As of the Record Date, 1,023,214 shares of common stock were issued and outstanding.
• The 2025 Equity Incentive Plan proposes 2,000,000 shares of common stock for awards to attract and retain talent.
• The company issued 5 shares of Series B Preferred Stock to Executive Chairman Paul K. Danner for $100 on July 15, 2025, which carry 220,000 votes per share (total 1,100,000 votes) on the authorized common stock increase proposal, mirrored proportionally to common stock votes, and will be redeemed upon the proposal's effectiveness.

Sentiment

Score: 6

Explanation: The filing presents standard annual meeting proposals, but the magnitude of the proposed authorized share increase and the specific mechanism used to secure its approval (Series B Preferred Stock with mirrored voting) introduce a degree of uncertainty and potential future dilution, balancing out the positive aspects of strategic flexibility and talent retention.

Positives

• The proposed 2025 Equity Incentive Plan aims to attract and retain key employees, directors, and consultants, aligning their interests with stockholders.
• Increasing authorized shares provides the company with flexibility for future capital-raising transactions, acquisitions, and employee compensation programs without immediate need for further stockholder meetings.
• The Board of Directors has a structured approach to risk oversight, with active involvement from the full Board and its committees.
• The company has adopted a clawback policy for executive compensation, enhancing corporate governance and accountability.

Negatives

• The proposed increase in authorized common stock from 1.7 million to 500 million shares is substantial and could lead to significant dilution of existing stockholders' percentage ownership if issued.
• The use of Series B Preferred Stock with supermajority voting rights (mirrored to common stock votes) for the authorized share increase proposal, while designed to reflect common stock preference, introduces a complex voting mechanism.
• A $500,000 payment to former CTO Barry Berler for cancellation of royalty obligations, due by May 31, 2021, has not been made, and a 2% royalty on intellectual property remains in place.
• Manning Elliott LLP resigned as the company's independent auditor in December 2023 due to 'internal risk tolerance metrics' related to the company's operations.

Risks

• Future issuance of additional common stock, if the authorized share increase is approved, will dilute the proportionate ownership and voting power of existing stockholders.
• The issuance of additional shares, or the possibility of their issuance, may depress the market price of the common stock.
• If the authorized common stock increase is not approved, the company's financing alternatives will be limited, potentially harming stockholder value and precluding strategic transactions.
• Failure to approve the 2025 Equity Incentive Plan would require the company to revise its compensation philosophy to cash-based programs, potentially impacting its ability to attract and retain talent.
• The company has an outstanding royalty obligation and a $500,000 payment due to a former CTO that has not been fulfilled, which could pose a financial or legal risk.

Future Outlook

The company anticipates that the proposed increase in authorized shares will provide necessary flexibility for future capital-raising, strategic acquisitions, and ongoing employee and director stock compensation programs. Approval of the 2025 Equity Incentive Plan is expected to ensure the continued ability to attract and retain key talent and align their interests with stockholders, avoiding a shift to less desirable cash-based compensation programs.

Management Comments

• The Board has determined that each proposal listed is in the best interests of the Company and its stockholders and has approved each proposal.
• The Board recommends a vote FOR each of the board of directors six nominees, FOR the Auditor Ratification Proposal, FOR the Incentive Plan Proposal, FOR the Authorized Common Stock Increase Proposal, and FOR the Adjournment Proposal.
• We expect that the requested increase in the number of shares would likely be sufficient to provide Plan awards for at least an additional year, at which time the Company would seek stockholder approval for the award of any additional shares under the Plan.
• The Board determined that it was in the best interests of the Company to provide for supermajority voting of the Series B Preferred Stock in order to obtain sufficient votes for the Authorized Common Stock Increase Proposal.

Industry Context

This filing reflects a common practice among growth-oriented companies, particularly in the healthcare or technology sectors, to seek increased authorized share counts to facilitate future financing, M&A activities, and talent retention through equity compensation. The emphasis on virtual annual meetings and digital proxy materials aligns with broader trends in corporate governance towards efficiency and accessibility. The change in auditors due to 'risk tolerance metrics' could suggest a shift in the auditor's assessment of the company's operational risk profile, which is a notable, though not necessarily negative, event in the financial reporting landscape.

Comparison to Industry Standards

• The proposed increase in authorized shares from 1.7 million to 500 million is a very significant jump, far exceeding typical incremental increases seen in established companies. While common for smaller, high-growth companies to seek flexibility, this magnitude warrants scrutiny regarding potential future dilution.
• The use of a 'supermajority voting' Series B Preferred Stock, where votes are mirrored to common stock, is an unusual mechanism. While the filing states it will not override common stock preference, it suggests a proactive measure to ensure passage of the authorized share increase, which could be viewed as a governance concern by some institutional investors.
• The 2025 Equity Incentive Plan's allocation of 2,000,000 shares, following previous plans (2022, 2023, 2024), indicates a consistent reliance on equity-based compensation, which is standard in the industry for attracting and retaining talent, especially in sectors like medical device or biotech where long-term incentives are crucial.
• The change in independent registered public accounting firm from Manning Elliott LLP to PKF OConnor Davies LLP due to 'internal risk tolerance metrics' is a red flag. While not explicitly a disagreement on accounting principles, such a change can sometimes precede or indicate underlying financial or operational challenges, contrasting with companies that maintain long-standing auditor relationships without such disclosures.

Management Changes

Corporate Governance

Legal Proceedings

• The company has not made a $500,000 payment to Barry Berler (former CTO) that was due by May 31, 2021, for the cancellation of a 2% royalty agreement on intellectual property. The 2% royalty remains in place.

Related Party Transactions

• Accounts payable and accrued liabilities included $22,000 as of March 31, 2025, and $99,500 as of December 31, 2024, payable to officers and directors of the Company. These amounts are unsecured, non-interest bearing, and due on demand.
• A royalty agreement with Barry Berler (former CTO) and Alan R. Blackman (former COO) provides for a 2% royalty on net sales derived from certain intellectual property. A $500,000 payment to Barry Berler for cancellation of all further royalty obligations, due by May 31, 2021, or upon a change of control, has not been made, and the 2% royalty remains in place.
• On July 15, 2025, the company issued and sold five (5) shares of Series B Preferred Stock to Paul K. Danner, Executive Chairman, for $100 in cash. These shares carry supermajority voting rights (220,000 votes per share) on the Authorized Common Stock Increase Proposal, with votes mirrored proportionally to common stock votes, and will be automatically redeemed upon the proposal's effectiveness.

Stakeholder Impact

• **Shareholders**: Potential for significant dilution if the proposed increase in authorized common stock is approved and subsequently issued. The Series B Preferred Stock voting mechanism for the authorized share increase could be perceived as impacting common shareholder voting power, despite the mirroring provision. The equity incentive plan aims to align employee and director interests with shareholders.
• **Employees/Directors/Consultants**: The proposed 2025 Equity Incentive Plan provides a mechanism for stock-based compensation, which is crucial for attracting and retaining talent. Executive compensation details are provided, showing significant option awards.
• **Creditors**: The disclosure of accounts payable to officers and directors, while unsecured and non-interest bearing, indicates internal short-term financing arrangements.
• **Regulatory Authorities**: The filing adheres to SEC and Nasdaq requirements, including disclosures on corporate governance, auditor changes, and related party transactions. The clawback policy aligns with regulatory trends.

Next Steps

• Stockholders to vote on the proposals at the Annual Meeting on August 22, 2025.
• If approved, the amendment to increase authorized common stock will become effective upon filing with the Nevada Secretary of State.
• The company will publish preliminary or final voting results in a Current Report on Form 8-K within four business days of the Annual Meeting.
• The Audit Committee will reconsider the appointment of PKF OConnor Davies LLP if stockholders do not ratify it.
• The company expects the requested increase in shares for the equity plan to be sufficient for at least an additional year, after which further stockholder approval may be sought for additional awards.

Key Dates

Keywords

Proxy Statement, Shareholder Meeting, Authorized Shares, Equity Incentive Plan, Corporate Governance, Dilution, SEC Filing, Stock Options, Board of Directors, Auditor Ratification, Capital Raise, Sharps Technology